RecruitingNCT06715579

Cardiac Angiosarcoma International Registry


Sponsor

Immune Oncology Research Institute

Enrollment

500 participants

Start Date

May 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are: 1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.


Eligibility

Plain Language Summary

Simplified for easier understanding

This is an international registry (database study) collecting clinical data from patients with cardiac angiosarcoma — a rare and aggressive cancer of the heart. The goal is to better understand this disease, how it is treated, and what outcomes patients experience. **You may be eligible if...** - You have a confirmed diagnosis of cardiac angiosarcoma (confirmed by biopsy) - You were diagnosed between January 2015 and January 2035 - You have received any treatment for the condition (surgery, chemo, immunotherapy, or radiation) - You are willing to share clinical data and participate in follow-up **You may NOT be eligible if...** - You do not consent to participate - Your cardiac involvement is secondary to another primary cancer (not a primary heart cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Yeolyan Hematology and Oncology Center

Yerevan, Armenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06715579